Alkem Labs launches first India-made semaglutide pre-filled syringes at ₹350
Alkem Laboratories is the first in India to launch semaglutide in single-shot pre-filled syringes, with prices starting at ₹350. This follows the March 2026 launch of semaglutide injection pens. The new format aims to improve patient access and convenience for managing Type 2 diabetes and obesity.
The introduction of a new product in a key therapeutic area can positively impact market share and revenue, but the exact impact depends on market adoption and competition.
The launch of a new, more accessible drug delivery format is a positive development for the company and patients.
Alkem Laboratories Limited has become the first company in India to launch semaglutide in single-shot pre-filled syringes. This new delivery format, available in multiple dose strengths with prices starting at ₹350, aims to enhance patient access and convenience while lowering entry barriers for semaglutide treatment.
The company received approval from the Drugs Controller General of India (DCGI) for these pre-filled syringes, intended for managing Type 2 diabetes mellitus and obesity as an adjunct to diet and exercise.
This launch follows Alkem's earlier introduction of semaglutide in injection pens in March 2026. The company also has regulatory approval for semaglutide vials, which are planned for a future launch.
Dr. Vikas Gupta, Chief Executive Officer of Alkem, stated that the pre-filled syringes offer wider choices for doctors and patients, complementing the existing pen options. He highlighted the importance of providing multiple, practical drug delivery formats to help more patients initiate and adhere to therapy, especially given the rising disease burden in India.
Alkem Laboratories is committed to providing high-quality, affordable medicines and improving patient care across key therapeutic areas.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under product launches. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.